31784-71-1

Basic information

• Product Name: 5-CHLORO-THIAZOLO[5,4-B]PYRIDIN-2-AMINE
• Synonyms: 5-CHLORO-THIAZOLO[5,4-B]PYRIDIN-2-AMINE;5-Chloro-thiazolo[5,4-b]-2-aMinopyridine;5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-aMine
• CAS NO: 31784-71-1
• Molecular Formula: C₆H₄ClN₃S
• Molecular Weight: 185.6341
• Mol File: 31784-71-1.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 356.8 °C at 760 mmHg
• Flash Point: 169.6 °C
• Appearance: /
• Density: 1.632 g/cm³
• Vapor Pressure: 2.85E-05mmHg at 25°C
• Refractive Index: 1.781
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.81±0.40(Predicted)
• CAS DataBase Reference: 5-CHLORO-THIAZOLO[5,4-B]PYRIDIN-2-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-THIAZOLO[5,4-B]PYRIDIN-2-AMINE(31784-71-1)
• EPA Substance Registry System: 5-CHLORO-THIAZOLO[5,4-B]PYRIDIN-2-AMINE(31784-71-1)

Safety Data

• Hazardous Substances Data: 31784-71-1(Hazardous Substances Data)

Usage

Uses

5-Chlorothiazolo[5,4-b]pyridin-2-amine

InChI:InChI=1/C6H4ClN3S/c7-4-2-1-3-5(10-4)11-6(8)9-3/h1-2H,(H2,8,9)

Upstream product

• 5350-93-6 6-Chloro-pyridin-3-ylamine 
• 333-20-0 potassium thioacyanate 
• 505-14-6 thiocyanogen 
• 540-72-7 sodium thiocyanide 
• 4548-45-2 2-chloro-5-nitropyridine 
• 131423-80-8 2-benzamido-5-chlorothiazolo<5,4-b>pyridine 
• 62476-56-6 3-amino-2,6-dichloropyridine 
• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 1050501-88-6 2-bromo-6-chloro-pyridin-3-amine 

Downstream Products

• 27467-92-1 3-amino-6-chloropyridine-2-thiol 
• 134666-20-9 4-Chloro-N-(5-chloro-thiazolo[5,4-b]pyridin-2-yl)-benzamidine 
• 128530-41-6 1-(5-Chloro-thiazolo[5,4-b]pyridin-2-yl)-3-(4-methoxy-benzoyl)-thiourea 
• 134666-19-6 2-Chloro-N-(5-chloro-thiazolo[5,4-b]pyridin-2-yl)-benzamidine 
• 134666-17-4 N-(5-Chloro-thiazolo[5,4-b]pyridin-2-yl)-2-methyl-benzamidine 
• 128530-40-5 1-(5-Chloro-thiazolo[5,4-b]pyridin-2-yl)-3-(4-methyl-benzoyl)-thiourea 
• 128530-39-2 1-(5-Chloro-thiazolo[5,4-b]pyridin-2-yl)-3-(3-methyl-benzoyl)-thiourea 
• 128530-42-7 1-(2-Chloro-benzoyl)-3-(5-chloro-thiazolo[5,4-b]pyridin-2-yl)-thiourea 
• 131423-82-0 2-Chloro-N-(5-chloro-thiazolo[5,4-b]pyridin-2-yl)-benzamide 
• 131423-87-5 2-Chloro-N-(5-methoxy-thiazolo[5,4-b]pyridin-2-yl)-benzamide 
• 131423-80-8 2-benzamido-5-chlorothiazolo<5,4-b>pyridine 
• 131423-85-3 N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)benzamide 
• 131423-81-9 N-(5-Chloro-thiazolo[5,4-b]pyridin-2-yl)-4-methyl-benzamide 
• 131423-86-4 N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-4-methylbenzamide 

Relevant articles and documents

Benzothiazole derivatives and their uses

The present invention relates to benzothiazole derivatives and their uses, specifically to compounds shown in formula I or stereoisomers thereof and pharmaceutically acceptable salts, solvates or prodrugs thereof, methods of preparation thereof, and pharmaceutical compositions containing the compounds, wherein the substituentsR1,R2,R8 , X, Y, Z, Q have the meaning given in the instruction manual. The present invention further relates to the application of compounds of formula I in the preparation of drugs for the treatment and / or prevention of sEH-mediated diseases, in particular in the preparation of drugs for the treatment of inflammatory diseases, cardiovascular and cerebrovascular diseases, diabetes mellitus, diabetic complications, diabetes-related diseases, fibrotic diseases, neurological and psychiatric diseases, pain, ulcerative diseases and the like.

NOVEL COMPOUNDS FOR DIAGNOSIS

The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity of a group of disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, a- synuclein, A-syn, α-syn, aSyn, SNCA, Non-amyloid beta component of Alzheimer's disease (AD) amyloid plaques, Non-A4 component of amyloid precursor, NACP) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease (PD). The instant compounds are particularly useful in the diagnosis of the preclinical state of such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament.

TETRAHYDROBENZOFURO[2,3-C]PYRIDINE AND BETA-CARBOLINE COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES

The present invention relates to novel compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).